MDGL at a glance
MADRIGAL PHARMACEUTICALS, INC. (MDGL, SEC CIK 1157601) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported revenue of $958.4 million (up 432.1% from FY2024) and a net loss of $288.3 million. Diluted EPS was -$12.85.
- As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding MADRIGAL PHARMACEUTICALS, INC. (MDGL) shares worth $3.9 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by BAKER BROS. ADVISORS LP on November 6, 2026 of 60,400 shares at $383.01 per share.
- In the last 90 days, MDGL insiders reported 5 open-market purchases ($35.0M) and 25 open-market sales ($6.7M) on Form 4, a net purchase of $28.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $958.4M
- +432.1% vs prior year
- Insiders · 90 days
- 5 buys · 25 sells
- Net +$28.4M
- 13F holders
- 38 funds
- $3.9B · +1 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: development and commercialization of pharmaceutical therapies for liver diseases, primarily noncirrhotic MASH
- New product: Launch and full-year commercialization of Rezdiffra in U.S. (approved Mar 2024) and market entry in Germany (Sep 2025)
- Strategic shift: Expansion of commercial infrastructure and geographic presence in Europe with emphasis on Rezdiffra sales growth
- Quantitative highlight: Product revenue surged to $958.4M in 2025 from $180.1M in 2024, with SG&A expenses increasing 87% to $813.8M reflecting expanded commercial activities
- Noteworthy fact: Entered $500M senior secured credit facility in July 2025, repaid and terminated prior $250M Hercules Loan Facility, signaling strengthened financial positioning
Risk Factors
- Regulatory risk: accelerated approval of Rezdiffra under FDA Subpart H pathway contingent on completing MAESTRO-NASH trials for full approval
- Geopolitical/macro risk: U.S. Medicare drug price negotiation program starting 2026 may cap prices and impose rebates on high-spend drugs like Rezdiffra
- Operational risk: dependence on third-party manufacturers to meet cGMP standards and commercial supply demands for Rezdiffra
- Competitive risk: potential competition from off-label use of marketed products and future MASH therapies impacting Rezdiffra market share
- Financial risk: reliance on successful third-party payor coverage and reimbursement, including Medicare, Medicaid, and PBMs, to support Rezdiffra sales
Management Discussion & Analysis
- No profitability or margin percentages disclosed
- Forward-looking focus on expanding Rezdiffra use via MAESTRO-NASH OUTCOMES trial and pipeline development of MGL-2086, ervogastat, siRNA programs
AI summary of the MDGL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly highlighted clinical-trial risk: FDA, EMA conditions, enrollment delays, supply shortages, or adverse effects could postpone approvals and commercialization
- Most materially updated financial risk: $2,187.4 million accumulated deficit despite $55.4 million quarterly net income
- Regulatory risk: FDA-required Rezdiffra post-marketing commitments and clinical trials could increase costs or delay commercialization
- Operational risk: Delayed trial completion could allow competitors to commercialize products first
- Liquidity risk: $961.8 million in cash, restricted cash, and marketable securities as of September 30, 2026
Management Discussion & Analysis
- Revenue $431.3M, up $144.0M YoY, driven by increased U.S. Rezdiffra demand
- Operating margin 13.0% vs negative 39.7% YoY, with operating income $56.0M vs loss of $114.0M
- Rezdiffra, sole reported product, generated $431.3M revenue and $37.8M cost of sales
- Cash, restricted cash and marketable securities $961.8M vs $988.6M at December 31, 2025
- Operating cash use $23.6M year-to-date, with $320.2M investing inflow and $15.4M financing inflow
AI summary of the MDGL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Investor-relevant figures and management commentary contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Rezdiffra Q3 net sales $431.3M, up 50% year over year, driving Madrigal’s first quarterly profitability
- Net income $55.4M, or $1.83 diluted EPS, versus $114.2M net loss in the prior-year quarter
Item 7.01: Regulation FD Disclosure
- August 12, 2026 press release announced the preceding material disclosure
- Exhibit 99.1 contains the press release, the key source for investor-relevant details
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from 8 to 9 directors with John C. Reed, M.D., Ph.D. joining as a Class II director through 2027
- Reed appointed to the Science and Technology Committee, adding senior scientific expertise to oversight
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the substantive financial details
Item EX-99.1: Item EX-99.1
- Rezdiffra Q2 net sales $364.3M, up 71% YoY, signaling accelerating commercial adoption and strong demand
- More than 49,000 patients treated by June 30, more than double 2Q25; active patients surpassed 50,000 earlier in July
AI summaries of MDGL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MDGL
Don't miss the next MDGL filing
- Alerts as it files. A push when MDGL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MDGL, by share count.
- Ask anything. An AI agent that reads every MDGL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Buy | Nov 6, 2026 | 60,400 | $383.01 |
| Kelley Shannon T | Sell | Nov 6, 2026 | 1,077 | $400.00 |
| BAKER BROS. ADVISORS LP | Buy | Nov 6, 2026 | 2,000 | $396.61 |
| BAKER BROS. ADVISORS LP | Buy | Nov 6, 2026 | 13,740 | $388.29 |
| BAKER BROS. ADVISORS LP | Buy | Nov 4, 2026 | 5,586 | $366.99 |
| BAKER BROS. ADVISORS LP | Buy | Nov 4, 2026 | 10,080 | $368.11 |
| Sibold William John | Sell | Sep 11, 2026 | 1,539 | $544.02 |
| Sibold William John | Sell | Sep 11, 2026 | 1,202 | $542.60 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $180.1M | $958.4M |
| Operating Income | - | -$497.9M | -$300.1M |
| Net Income | -$373.6M | -$465.9M | -$288.3M |
| Op. Margin | - | -276.4% | -31.3% |
| Net Margin | - | -258.6% | -30.1% |
| Balance Sheet | |||
| Total Assets | $640.5M | $1.0B | $1.3B |
| Equity | - | $754.4M | $602.7M |
| ROE | - | -61.8% | -47.8% |
| Per Share | |||
| EPS | $-19.99 | $-21.90 | $-12.85 |
| Cash Flow | |||
| Operating CF | - | -$455.6M | -$189.6M |
| CapEx | $1.5M | $1.5M | $467K |
Source: XBRL data in MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MDGL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 38 | $3.94B |
| Q2 2026 | 37 | $3.94B |
| Q1 2026 | 38 | $4.35B |
| Q4 2025 | 33 | $5.12B |
| Q3 2025 | 31 | $4.13B |
| Q2 2025 | 30 | $2.72B |
| Q1 2025 | 29 | $2.27B |
| Q4 2024 | 22 | $1.95B |
- AQR Capital Management+620.4K (+3920%)
- Ameriprise Financial+217.1K (+94%)
- Two Sigma Investments+185.0K (+32682%)
- Paulson & Co+151.6K (+11%)
- Citigroup+85.8K (+230%)
- Citadel Advisors LLC−432.3K (-85%)
- Goldman Sachs Group−99.2K (-40%)
- Millennium Management−72.9K (-90%)
- Vanguard Portfolio Management LLC−20.7K (-3%)
- D.E. Shaw & Co−5.1K (-15%)
- FMR LLC (Fidelity)−356.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 258 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MDGL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 8-K | Jun 17, 2026 | - | Analysis | - |
| 4 | Jun 1, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 8-K | Apr 28, 2026 | - | Analysis | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
MDGL SEC filings: frequently asked questions
Are MDGL insiders buying or selling?
In the last 90 days, MADRIGAL PHARMACEUTICALS, INC. (MDGL) officers, directors and 10% owners reported 5 open-market purchases worth $35.0 million by 1 insider and 25 open-market sales worth $6.7 million by 2 insiders on Form 4, a net purchase of $28.4 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MDGL stock?
As of September 30, 2026, the largest MADRIGAL PHARMACEUTICALS, INC. (MDGL) holders among the 13F filers tracked by SignalX were Paulson & Co ($751.7 million), BlackRock ($624.4 million), Vanguard Capital Management LLC ($426.7 million), Vanguard Portfolio Management LLC ($383.5 million), AQR Capital Management ($320.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MDGL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported revenue of $958.4 million (up 432.1% from FY2024) and a net loss of $288.3 million. Diluted EPS was -$12.85. The figures come from the XBRL data in the 10-K.
What are the main risks in MDGL's latest 10-K?
In the 10-K filed February 19, 2026, MADRIGAL PHARMACEUTICALS, INC. (MDGL) flagged: Regulatory risk: accelerated approval of Rezdiffra under FDA Subpart H pathway contingent on completing MAESTRO-NASH trials for full approval. Geopolitical/macro risk: U.S. Medicare drug price negotiation program starting 2026 may cap prices and impose rebates on high-spend drugs like Rezdiffra. (AI summary of the Risk Factors section.)
What did MDGL report in its latest 8-K?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest MDGL SEC filings?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 6, 2026.
What is MDGL's SEC CIK number?
MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s SEC Central Index Key (CIK) is 1157601. EDGAR lists every MDGL filing under that number.
Ask anything about MDGL
The research agent reads MDGL's filings, financials, insider trades and 13F holders, then answers with sources.